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Ititroduction 
The replacement of chlorofluorocarbon (CFC) propellants 
with hydrofluoroalkane-134a (HFA), and the introduction 
of a pressurized metered dose inhaler (pMDI) in the recent 
reformulation of beclomethasone dipropionate (BDP), has 
resulted in a product with aerosol particles of a smaller 
mean mass aerodynamic diameter (MMAD) than conven- 
tional CFC-BDP MDIs (1,2). 
(3). While conventional CFC-BDP inhalers produce rela- 
tively large particles with a mean size of 3.5-4*0pm, the 
new HFA-BDP formulation delivers an extrafine aerosol 
of active compound with a mean particle size of l-1 pm 
(Fig. I) in a warmer and more gentle spray (Fig. 2) (4). This 
would be expected to improve drug deposition throughout 
the large and small airways. 
The purpose of the current report is to present data 
showing that this new formulation of HFA-BDP 
(QVARTM, 3M Pharmaceuticals, St Paul, MN, U.S.A.) is 
at least as effective in alleviating the symptoms of asthma as 
conventional CFC-BDP inhalers, when used at a signifi- 
cantly lower dose. To support this assumption, data 
comparing the new HFA-BDP formulation with conven- 
tional CFC-BDP formulations is presented, namely: 
patterns of inhaled corticosteroid (ICS) distribution in the 
oropharynx and lungs; efficacy/potency ratios as measured 
by pharmacodynamic analysis; the clinical effect of switch- 
ing from a CFC-BDP to a half dose of HFA-BDP, and the 
efficacy of long-term use of HFA-BDP in patients with 
moderate asthma. 
The lung distribution of HFA-BDP and CFC-BDP in the 
pulmonary and oropharyngeal airways has been compared 
using technetium 99 m labelled BDP (5). Even after optimal 
use, CFC-BDP MDIs typically deliver no more than 10% 
of the inhaled drug to the lungs, the residual product 
remaining in the oropharynx where it provides little 
therapeutic benefit. In contrast, the new HFA-BDP 
formulation delivers approximately 60% of the drug to 
the lungs. 
Efficacy/potency ratio 
HFA-BDP 
HFA-BDP is a completely new preparation of BDP, which 
has been recently formulated to meet CFC-free require- 
ments. To accomodate the new formulation, which, unlike 
CFC-MDIs, is a solution rather than a suspension of drug 
in propellant, different parts of the inhaler, including the 
valve (elastomers, seals and gasket) have been modified. In 
addition, to optimize ICS deposition in the airways, the 
actuator has been redesigned. 
By improving drug delivery to the airways, the new HFA- 
BDP formulation should also enhance respiratory function. 
To test this assumption, a protocol was designed to 
compare CFC-BDP with HFA-BDP in over 300 patients 
with moderate asthma who required regular use of ICS. In 
this multicentre, randomized, parallel group, blinded study, 
following a run-in period of 7 to I4 days (during which time 
the patients continued to receive their usual ICS medica- 
tion), the patients entered an ICS washout period during 
which dependence on ICS to maintain asthma control was 
established. Subsequently, patients were randomized to 
70, 1 
The deposition pattern of BDP particles in the lungs is a 
function of several factors, including respiratory tract 
geometry, airflow, particle diameter and density, and the 
time spent in the airways during breath-holding. Particles 
are distributed in the airways according to their MMAD, 
smaller particles more effectively penetrating the more 
distal regions of the lung: upper airways (MMAD = 3 pm); 
main bronchi (MMAD = 2 pm); peripheral airways 
(MMAD = I *5 pm); more distal airways (MMAD = O-5 pm) 
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FIG. 1. Particle size distribution of BDP in CFC suspension 
and HFA solution. -: CON-BDP; ---: HFA-BDP. 
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FIG. 2. Plume effect. 
26 , I 
3 
!24- 
Relative dose ratio 2.6 
3 24 
(95% CIl.l- 11.6) 
c- 
; 22- .’ .’ 
- g .’ 20- 
.B 
1 18- 
d 
8 
8 
16- 
3 14- 
a ,P 
n ”  
loo 150 400 800 
Total daily dose @g day-‘) Bog scale] 
FIG. 3. Regression analysis of change from baseline in 
FEV, as % predicted at week 6. -: CON-BDP; --: HFA- 
BDP. 
receive one of six possible treatments (100, 400 or 
800pgday-’ of CFC-BDP or 100, 400 or 800pgday-’ of 
HFA-BDP) for a period of 6 weeks (6). Both formulations 
were of the SOpgpuff-’ ex-valve strength, and a double- 
dummy, modified blind technique was used, requiring nine 
puffs, twice daily, from three different MDIs. Spacers were 
not allowed. Treatment efficacy was assessed during almost 
daily patient visits. In addition, the patients’ MD1 
technique was reviewed and corrected where necessary. 
The study showed a clear benefit for HFA-BDP 
treatment compared to CFC-BDP treatment at all doses, 
as measured by both the mean change from baseline in 
forced expiratory volume in 1 set (FEV,) and in forced 
expiratory flow between 25% and 75% of vital capacity 
(FEFa,,&. The latter indicates the enhanced distal effect 
of HFA-BDP vs. CFC-BDP in the respiratory tract. 
Regression analysis of change from baseline in FEV, as a 
percentage of predicted at week 6 (Fig. 3) and percentage 
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FIG. 4. Regression analysis of percentage change from 
baseline in FEFzs-7soj0 at week 6. -: CON-BDP; --: 
HFA-BDP. 
change from baseline in FEF2s7S0,0 at week 6 (Fig. 4) 
concluded that there was a shift to the left for HFA-BDP 
compared to CFC-BDP. Using these data, a dose- 
comparison relationship indicates that it would take 2.6 
and 3.2 times the dose of CFC-BDP (compared to 
HFA-BDP) to obtain the same improvement in FEVi and 
FEFzs-r5%, respectively, as predicted for HFA-BDP. 
The effects of switching from a 
conventional CFC-BDP to an HFA- 
BDP at a ratio of 2.5:1 
To further confirm the potency ratio between HFA-BDP 
and conventional CFC-BDPs a total of 149 patients were 
included in a double-blind, double-dummy, parallel-group, 
multicentre, randomized study, which compared the 
efficacy of HFA-BDP 400 pgday - ’ W. CFC-BDP 
lOOOpgday-’ over a IO-week period in patients with 
moderate asthma (7). Prior to randomization, all patients 
received CFC-BDP IOOOpgday-’ during a 4-week run-in 
period. No significant difference in symptom scores and 
pulmonary function parameters [morning peak expiratory 
flow (AM PEF), FEV,, and PCzaFEVi] was recorded 
between the two groups at the end of treatment (Fig. 5), 
indicating that HFA-BDP 400 pgday-’ provides an 
equivalent control of asthma symptoms to CFC-BDP 
IOOOpgday-‘. This result confirms the prediction of a 
2*5:1 potency ratio between the two formulations. 
Long-term maintenance of asthma 
control 
The long-term efficacy of HFA-BDP (200-800pgday-‘) 
was compared to CFC-BDP (400-1600 pg day-‘) in a 
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FIG. 5. Symptom scores and pulmonary function parameters: HFA-BDP 400pg/day vs. CFC-BDP lOOOpgday-‘. -A-: 
HFA-BDP; --¤-: CON-BDP. - 
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FIG. 6. Time to onset of first occurrence of acute asthma 
episode or increased asthma symptoms. -: CON-BDP; 
--: HFA-BDP. 
randomized prospective study of 1Zmonths’ duration (8). treatment following the switch from CFC-BDP to half the 
Patients participating in the study had a 26 month history dose of HFA-BDP. In addition, there was no significant 
of asthma and were receiving CFC-BDP 400- difference between the time to onset of acute exacerbations 
1600pgday-‘. Patients were randomized to the same dose or increased asthma symptoms (Fig. 6) (9). Finally, the 
of CFC-BDP (n = 119) or to approximately half the dose of long-term Juniper overall Quality of Life score (lo), was 
HFA-BDP (n = 354). The study clearly demonstrated that significantly higher in the HFA-BDP group after 12 months 
asthma control was maintained during the 12 months of of treatment (Fig. 7) (8). 
P = 0.019 
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FIG. 7. Overall Quality of Life Juniper score. H: CON- 
BDP; 0: HFA-BDP. 
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Conclusion 
In conclusion, compared to conventional CFC-BDP for- 
mulations, the new HFA-BDP formulation improves drug 
deposition in the lungs while reducing oropharyngeal 
deposition. The resulting greater efficacy of the new 
formulation is proportional to the efficiency of lung 
delivery, which is a result of improvements in the design 
of the inhalation device and the use of HFA 134 as a 
propellant. Other advantages of the new formulation 
include lower dosage requirements (2-2.5:1 dose ratio) 
and an effective long-term maintenance of asthma control 
with clear patient benefits in quality of life. 
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